Real-life patterns of use and effectiveness of bortezomib: the VESUVE cohort study

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Leukemia and Lymphoma

• Publication date

  2014-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3109/10428194.2013.806801PMID 23808815
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chemotherapy and targeted agents for colorectal cancer in a real‐life setting anticipate guidelines: the COLCHIC cohort study

  2013cited by this paper
• Treatment Options for Relapsed and Refractory Multiple Myeloma

  2011cited by this paper
• Novel drugs in myeloma: harnessing tumour biology to treat myeloma.

  2011cited by this paper
• Global cancer statistics

  2011cited by this paper
• Therapy of relapsed and refractory multiple myeloma.

  2011cited by this paper
• Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies.

  2011cited by this paper
• Firstline treatment and maintenance in newly diagnosed multiple myeloma patients.

  2011cited by this paper
• Relapsed and Refractory Multiple Myeloma

  2010cited by this paper
• Oncology: Treatment of Multiple Myeloma in the Targeted Therapy Era

  2009cited by this paper
• Impact of Prescriber Nonresponse on Patient Representativeness

  2008cited by this paper
• Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.

  2007cited by this paper
• Daily practice use of Bortezomib in relapsed/refractory multiple myeloma. Safety/efficacy results of a compassionate use program in Switzerland.

  2007cited by this paper
• International uniform response criteria for multiple myeloma

  2007cited by this paper
• WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues

  2007cited by this paper
• Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.

  2007cited by this paper
• Targeting the proteasome in mantle cell lymphoma: A promising therapeutic approach

  2006cited by this paper
• Extended follow‐up of a phase II trial in relapsed, refractory multiple myeloma:

  2006cited by this paper
• International uniform response criteria for multiple myeloma

  2006cited by this paper
• Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

  2005cited by this paper
• A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

  2004cited by this paper
• A phase 2 study of bortezomib in relapsed, refractory myeloma.

  2003cited by this paper

• Pharmacoepidemiology for oncology clinical practice: Foundations, state of the art and perspectives.

  2021cites this paper
• Pharmacovigilance - The next chapter.

  2019cites this paper
• The value of a health insurance database to conduct pharmacoepidemiological studies in oncology.

  2019cites this paper
• Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort

  2019cites this paper
• Bortezomib‐based therapy for relapsed/refractory multiple myeloma in real‐world medical practice

  2018cites this paper
• Real life management of patients hospitalized with multiple myeloma in France

  2018cites this paper
• Real‐life patterns of use, safety and effectiveness of sunitinib in first‐line therapy of metastatic renal cell carcinoma: the SANTORIN cohort study

  2017cites this paper
• Patterns and effectiveness of bortezomib use according to age in the VESUVE cohort

  2016cites this paper
• Case-adjusted bortezomib-based strategy in routine therapy of relapsed/refractory multiple myeloma shown to be highly effective--a report by Polish Myeloma Study Group.

  2014cites this paper
• Pharmacoepidemiology

  1996cites this paper